Total assets have halved 54% to $260.1M and equity has fallen 64% to $153.4M even as total debt only declined modestly to $75.7M, driving the D/E ratio from 0.24 to 0.49 and leaving cash of $32.4M covering only a few months of operations.
Fate Therapeutics, Inc. (FATE) balance sheet — 15-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Total Current Assets | 144.26M | 208.7M | 291.91M | 331.54M | 502.07M | 633.41M | 494.32M | 227.09M | 205.2M | 102.6M | 93.32M | 65.65M | 49.87M | 54.65M | 9.79M | 6.69M |
| Cash & Short-Term Investments | 139.13M | 203.66M | 279.07M | 315.18M | 436.23M | 615.91M | 482.92M | 221.43M | 201.01M | 100.95M | 92.11M | 64.81M | 49.1M | 54.04M | 9.09M | 6.39M |
| Cash Only | 43.94M | 46.63M | 36.06M | 41.87M | 61.33M | 133.58M | 167.35M | 99.81M | 190.51M | 88.95M | 88.61M | 64.81M | 49.1M | 54.04M | 9.09M | 6.39M |
| Short-Term Investments | 95.19M | 157.03M | 243.01M | 273.31M | 374.89M | 482.33M | 315.57M | 121.61M | 10.49M | 12M | 3.5M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 479K | 916K | 3.54M | 1.83M | 38.48M | 8.68M | 5.51M | 0 | 500K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 53.83 | 50.31 | 94.76 | 10.49 | 145.85 | 56.7 | 64.04 | - | 38.5 | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 4.13M | 9.3M | 900K | 27.37M | 1.1M | 5.89M | 5.66M | 0 | 1.65M | 1.21M | 843K | 771K | 615K | 0 | 0 |
| Total Non-Current Assets | 94.02M | 110.23M | 148.78M | 174.68M | 203.49M | 288.04M | 128.13M | 75.19M | 7.84M | 2.7M | 1.73M | 2.31M | 1.33M | 932K | 1.28M | 1.16M |
| Property, Plant & Equipment | 88.92M | 98.53M | 110.89M | 158.51M | 66.07M | 162.25M | 99.39M | 22.75M | 5.13M | 2.55M | 1.58M | 2.16M | 1.2M | 810K | 1.16M | 1.04M |
| Fixed Asset Turnover | 0.05x | 0.07x | 0.12x | 0.40x | 1.46x | 0.34x | 0.32x | 0.47x | 0.92x | 1.61x | 2.79x | 1.13x | - | 1.20x | 2.30x | 1.12x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.47M | 1.47M | 27.66M | 980K | 4.94M | 100.66M | 28.73M | 39.44M | 2.19M | 122K | 122K | 122K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5.1M | 10.23M | 10.24M | 15.19M | 132.48M | 25.13M | 9K | 12.99M | 526K | 24K | 24K | 24K | 132K | 122K | 122K | 122K |
| Total Assets | 238.28M | 318.94M | 440.69M | 506.22M | 705.56M | 921.46M | 622.46M | 302.27M | 213.03M | 105.29M | 95.05M | 67.96M | 51.2M | 55.58M | 11.08M | 7.85M |
| Asset Turnover | 0.02x | 0.02x | 0.03x | 0.13x | 0.14x | 0.06x | 0.05x | 0.04x | 0.02x | 0.04x | 0.05x | 0.04x | - | 0.02x | 0.24x | 0.15x |
| Asset Growth % | -116.84% | -27.63% | -12.94% | -28.25% | -23.43% | 48.04% | 105.92% | 41.89% | 102.33% | 10.78% | 39.86% | 32.72% | -7.88% | 401.83% | 41.06% | - |
| Total Current Liabilities | 32.69M | 36.07M | 38.52M | 39.09M | 114.05M | 81.28M | 85.56M | 27.81M | 27.26M | 11.05M | 15.19M | 13.44M | 4.58M | 4.6M | 4.85M | 3.67M |
| Accounts Payable | 2.92M | 2.66M | 9.37M | 4.72M | 8.27M | 8.61M | 6.28M | 5.82M | 4.21M | 1.68M | 934K | 996K | 645K | 682K | 1.23M | 1.86M |
| Days Payables Outstanding | 197.57 | 75.14 | 28.84 | 10.96 | 219.27 | 537.33 | 18.26 | - | 27.4 | 17.83 | 12.89 | 18.3 | 14.32 | 20.73 | 37.35 | - |
| Short-Term Debt | 0 | 0 | 0 | 6.18M | 0 | 0 | 3.35M | 0 | 2.44M | 0 | 8.19M | 7.55M | 1.55M | 1.73M | 1.94M | 1.25M |
| Deferred Revenue (Current) | 963K | 381K | 393K | 685K | 42.23M | 21.48M | 21.14M | 2.79M | 7.59M | 2.1M | 2.1M | 2.4M | 2.26M | 2.09M | 63K | 146K |
| Other Current Liabilities | 9.51M | 8.45M | 11.64M | 16.95M | 40.03M | 3.2M | 49.97M | 12.18M | 10.09M | 5.5M | 2.46M | 1.5M | 130K | 147K | 327K | 221K |
| Current Ratio | 4.41x | 5.79x | 7.58x | 8.48x | 4.40x | 7.79x | 5.78x | 8.17x | 7.53x | 9.29x | 6.14x | 4.88x | 10.89x | 11.88x | 2.02x | 1.82x |
| Quick Ratio | 4.41x | 5.79x | 7.58x | 8.48x | 4.40x | 7.79x | 5.78x | 8.17x | 7.53x | 9.29x | 6.14x | 4.88x | 10.89x | 11.88x | 2.02x | 1.82x |
| Cash Conversion Cycle | -143.74 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 72.55M | 75.68M | 83.45M | 98.71M | 107.57M | 161.33M | 152.45M | 29.71M | 25.3M | 17.05M | 6.71M | 16.48M | 18.28M | 135K | 59.05M | 54.86M |
| Long-Term Debt | 0 | 73.29M | 0 | 0 | 0 | 0 | 0 | 0 | 12.45M | 14.81M | 2.5M | 10.69M | 18.08M | 0 | 1.73M | 3.59M |
| Capital Lease Obligations | 140.14M | 0 | 77.85M | 97.36M | 103.71M | 109.24M | 93.94M | 25.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.17M | 2.4M | 5.6M | 1.35M | 3.86M | 24.97M | 12.48M | 702K | 5.35M | 1.52M | 1.38M | 857K | 200K | 135K | 57.32M | 51.27M |
| Total Liabilities | 105.24M | 111.75M | 121.97M | 137.8M | 221.62M | 242.62M | 238.01M | 57.52M | 52.56M | 28.1M | 21.89M | 29.92M | 22.86M | 4.74M | 63.9M | 58.53M |
| Total Debt | 74.49M | 77.85M | 85.27M | 103.54M | 109.34M | 114.82M | 97.3M | 26.93M | 14.88M | 14.81M | 10.69M | 18.24M | 19.63M | 1.73M | 3.67M | 4.84M |
| Net Debt | 30.55M | 31.22M | 49.21M | 61.67M | 48.01M | -18.77M | -70.05M | -72.89M | -175.63M | -74.14M | -77.92M | -46.57M | -29.47M | -52.3M | -5.41M | -1.55M |
| Debt / Equity | 0.56x | 0.38x | 0.27x | 0.28x | 0.23x | 0.17x | 0.25x | 0.11x | 0.09x | 0.19x | 0.15x | 0.48x | 0.69x | 0.03x | - | - |
| Debt / EBITDA | -0.62x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.26x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | -55.02x | -38.27x | -32.87x | -19.44x | -12.51x | -46.15x | -25.25x | -28.24x | -104.72x |
| Total Equity | 133.03M | 207.18M | 318.73M | 368.42M | 483.94M | 678.84M | 384.44M | 244.76M | 160.47M | 77.19M | 73.15M | 38.04M | 28.34M | 50.85M | -52.83M | -50.68M |
| Equity Growth % | -157.14% | -35% | -13.49% | -23.87% | -28.71% | 76.58% | 57.07% | 52.53% | 107.89% | 5.52% | 92.32% | 34.22% | -44.27% | 196.26% | -4.23% | - |
| Book Value per Share | 1.08 | 1.74 | 2.80 | 3.74 | 5.00 | 7.16 | 4.67 | 3.59 | 2.86 | 1.84 | 2.30 | 1.49 | 1.39 | 2.57 | -5.96 | -5.72 |
| Total Shareholders' Equity | 133.03M | 207.18M | 318.73M | 368.42M | 483.94M | 678.84M | 384.44M | 244.76M | 160.47M | 77.19M | 73.15M | 38.04M | 28.34M | 50.85M | -52.83M | -50.68M |
| Common Stock | 122K | 115K | 114K | 99K | 97K | 96K | 88K | 76K | 65K | 53K | 41K | 29K | 21K | 20K | 1K | 1K |
| Retained Earnings | -1.63B | -1.53B | -1.4B | -1.21B | -1.05B | -769.08M | -556.93M | -383.55M | -285.4M | -218.8M | -175.85M | -142.38M | -112.39M | -86.51M | -65.61M | -51.38M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -155K | 116K | 268K | 15K | -1.85M | -762K | 70K | 22K | -2K | -3K | -1K | -3.47M | -2.79M | -2.3M | -1.75M | -1.16M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying FATE stock.
As of 2025, Fate Therapeutics, Inc. (FATE) had total assets of $318.9M including $208.7M in current assets.
Fate Therapeutics, Inc. (FATE) carries total debt of $77.8M, offset by $203.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Fate Therapeutics, Inc. (FATE) has total shareholders' equity (book value) of $207.2M ($1.74 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Fate Therapeutics, Inc. (FATE) reported a current ratio of 5.79x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash depletion outpacing financing options
Metrics are mathematically derived from official filings.
Asset Base Halves Over Ten Quarters
FATE's total assets have contracted 54%, from $569.9M in 2024Q1 to $260.1M in 2026Q2, while equity fell 64% to $153.4M, per the company's quarterly balance sheets, a trajectory driven by sustained operating losses consuming the balance sheet rather than by divestitures.
The roughly $31M average quarterly decline in total assets tracks closely with the operating losses documented in FATE's income statements, implying the company is funding its burn by liquidating balance-sheet resources rather than through external capital raises. Importantly, this erosion shows no sign of decelerating: the last four quarters removed about $185M of assets, a pace that, if sustained, would exhaust the remaining $260M asset base well before any commercial inflection. For a pre-revenue biotech, this pattern signals deteriorating business quality trajectory rather than temporary working-capital volatility.
Stable Borrowings Mask Equity-Driven Leverage Drift
Total debt has declined modestly from $102.1M to $75.7M over ten quarters, yet FATE's debt-to-equity ratio has doubled from 0.24 to 0.49, based on FATE's reported figures, because the equity denominator is shrinking far faster than obligations are being retired.
The near-flat debt trajectory suggests FATE is servicing but not aggressively pre-paying its obligations, meaning the leverage drift is a symptom of balance-sheet erosion rather than new borrowing — a distinction that matters for assessing whether the capital structure is strategically leveraged or deteriorating by default. At 0.49, FATE now carries materially higher relative leverage than CRSP (0.21), NTLA (0.14), and BEAM (0.24), though its absolute debt quantum remains modest. Investors should monitor whether the company draws further on debt facilities to bridge its cash shortfall, which would compound an already worsening leverage profile.
Cash Reserves Fall to Emergency Territory
Cash declined from $121.3M in 2024Q1 to $32.4M in 2026Q2, per FATE's balance sheets, and against roughly $23.5M of quarterly free cash outflow reported for 2026Q2, the unencumbered cash balance appears to cover only a few months of operations absent new financing.
The current ratio of 4.85 in 2026Q2, though down sharply from 8.69 two years prior, appears difficult to reconcile with the $260.1M total asset base and $32.4M cash line, so the true composition of FATE's current assets warrants verification before relying on the ratio as a liquidity buffer. What is unambiguous is the direction: cash has fallen for nine consecutive quarters, and the modest sequential upticks (e.g., $39.6M to $32.4M reversal in Q2) suggest no replenishment event occurred during the period. Compared with peers holding $146M–$355M in cash, FATE's liquidity position appears the most exposed to a near-term financing or restructuring decision.
Shrinking PPE Confirms Outsourced Manufacturing Model
Net property, plant, and equipment has fallen 40%, from $152.7M in 2024Q1 to $92.1M in 2026Q2, while goodwill remained at zero across all ten quarters, per FATE's filings, indicating depreciation is consuming the asset base faster than replacement investment occurs.
Consistent with the cash flow finding that cumulative capex of ~$8.2M is dwarfed by ~$36.7M of cumulative depreciation, the PPE decline implies FATE's legacy manufacturing infrastructure is being run down rather than maintained, reinforcing an increasingly asset-light, outsourced production footprint. This carries a dual read: the absence of goodwill eliminates impairment risk entirely, a genuine relative strength, but the depreciating PPE base suggests limited in-house production capacity remains available to support any future commercial scale-up without incremental capital. The $92.1M residual book value may therefore overstate the productive capacity currently embedded in FATE's operations.
Book Equity Erodes Despite SBC Cushion
Shareholders' equity declined from $426.1M to $153.4M over ten quarters while accumulated deficits deepened to -$1.6B, per FATE's balance sheets, with cumulative net losses exceeding equity erosion — a gap suggesting stock-based compensation partially offset, but did not prevent, the deterioration in book value.
The ~$273M equity decline is smaller than the ~$384M of cumulative net losses cited in FATE's income statements, implying roughly $74M of stock-based compensation and other non-cash items propped up book equity during the period. However, as SBC has contracted 68% to $3.5M per quarter, this cushion is disappearing, meaning future equity erosion should track cash losses more directly. With no buybacks or dividends deployed across the decade's quarters, the equity contraction is entirely loss-driven — an unambiguous signal that the remaining $153.4M book value is being consumed to fund ongoing operations rather than preserved for strategic optionality.
Deferred Revenue Vacuum Removes Forward Cover
Deferred revenue fell to zero in 2026Q2 from $600K in 2024Q3, per FATE's reported filings, eliminating even the modest contracted-backlog signal that previously implied near-term collaboration infusions and leaving the balance sheet with essentially no forward revenue visibility.
The non-obvious risk here is the interaction between a zero-deferred-revenue position and FATE's milestone-dependent revenue model: without any contracted liabilities representing pre-paid partner obligations, there is no balance-sheet evidence of committed future collaboration cash, making the remaining $32.4M cash position the sole measurable buffer. This contrasts with the income statement's occasional 100% gross-margin quarters, which create an illusion of commercial viability that the balance sheet does not corroborate. Combined with the doubled D/E ratio and nine consecutive quarters of cash decline, the balance sheet suggests FATE's headline solvency metrics understate the immediacy of its financing need.